Literature DB >> 26163590

Dual Function of the IRF8 Transcription Factor in Autoimmune Uveitis: Loss of IRF8 in T Cells Exacerbates Uveitis, Whereas Irf8 Deletion in the Retina Confers Protection.

Sung-Hye Kim1, Jenna Burton1, Cheng-Rong Yu1, Lin Sun1, Chang He1, Hongsheng Wang2, Herbert C Morse2, Charles E Egwuagu3.   

Abstract

IFN regulatory factor 8 (IRF8) is constitutively expressed in monocytes and B cells and plays a critical role in the functional maturation of microglia cells. It is induced in T cells following Ag stimulation, but its functions are less well understood. However, recent studies in mice with T cell-specific Irf8 disruption under direction of the Lck promoter (LCK-IRF8KO) suggest that IRF8 directs a silencing program for Th17 differentiation, and IL-17 production is markedly increased in IRF8-deficient T cells. Paradoxically, loss of IRF8 in T cells has no effect on the development or severity of experimental autoimmune encephalomyelitis (EAE), although exacerbating colitis in a mouse colitis model. In contrast, mice with a macrophage/microglia-specific Irf8 disruption are resistant to EAE, further confounding our understanding of the roles of IRF8 in host immunity and autoimmunity. To clarify the role of IRF8 in autoimmune diseases, we have generated two mouse strains with targeted deletion of Irf8 in retinal cells, including microglial cells and a third mouse strain with targeted Irf8 deletion in T cells under direction of the nonpromiscuous, CD4 promoter (CD4-IRF8KO). In contrast to the report that IRF8 deletion in T cells has no effect on EAE, experimental autoimmune uveitis is exacerbated in CD4-IRF8KO mice and disease enhancement correlates with significant expansion of Th17 cells and a reduction in T regulatory cells. In contrast to CD4-IRF8KO mice, Irf8 deletion in retinal cells confers protection from uveitis, underscoring divergent and tissue-specific roles of IRF8 in host immunity. These results raise a cautionary note in the context of therapeutic targeting of IRF8.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26163590      PMCID: PMC4530071          DOI: 10.4049/jimmunol.1500653

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  46 in total

1.  Pax6 is required for the multipotent state of retinal progenitor cells.

Authors:  T Marquardt; R Ashery-Padan; N Andrejewski; R Scardigli; F Guillemot; P Gruss
Journal:  Cell       Date:  2001-04-06       Impact factor: 41.582

Review 2.  The natural history of uveitis.

Authors:  R B Nussenblatt
Journal:  Int Ophthalmol       Date:  1990-10       Impact factor: 2.031

3.  Autoreactive memory CD4+ T lymphocytes that mediate chronic uveitis reside in the bone marrow through STAT3-dependent mechanisms.

Authors:  Hyun-Mee Oh; Cheng-Rong Yu; Yongjun Lee; Chi-Chao Chan; Arvydas Maminishkis; Charles E Egwuagu
Journal:  J Immunol       Date:  2011-08-10       Impact factor: 5.422

Review 4.  Roles of interferon-regulatory factors in T-helper-cell differentiation.

Authors:  Michael Lohoff; Tak W Mak
Journal:  Nat Rev Immunol       Date:  2005-02       Impact factor: 53.106

5.  Persistence of IL-2 expressing Th17 cells in healthy humans and experimental autoimmune uveitis.

Authors:  Cheng-Rong Yu; Hyun-Mee Oh; Nady Golestaneh; Ahjoku Amadi-Obi; Yun S Lee; Amarachi Eseonu; Rashid M Mahdi; Charles E Egwuagu
Journal:  Eur J Immunol       Date:  2011-10-27       Impact factor: 5.532

6.  Interferon regulatory factor 8 integrates T-cell receptor and cytokine-signaling pathways and drives effector differentiation of CD8 T cells.

Authors:  Fumi Miyagawa; Hong Zhang; Atshushi Terunuma; Keiko Ozato; Yutaka Tagaya; Stephen I Katz
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-10       Impact factor: 11.205

7.  TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1.

Authors:  Ahjoku Amadi-Obi; Cheng-Rong Yu; Xuebin Liu; Rashid M Mahdi; Grace Levy Clarke; Robert B Nussenblatt; Igal Gery; Yun Sang Lee; Charles E Egwuagu
Journal:  Nat Med       Date:  2007-05-13       Impact factor: 53.440

8.  A clinical grading system for retinal inflammation in the chronic model of experimental autoimmune uveoretinitis using digital fundus images.

Authors:  Heping Xu; Philippe Koch; Mei Chen; Annie Lau; Delyth M Reid; John V Forrester
Journal:  Exp Eye Res       Date:  2008-06-26       Impact factor: 3.467

9.  The clinical time-course of experimental autoimmune uveoretinitis using topical endoscopic fundal imaging with histologic and cellular infiltrate correlation.

Authors:  David A Copland; Michael S Wertheim; W John Armitage; Lindsay B Nicholson; Ben J E Raveney; Andrew D Dick
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-08-29       Impact factor: 4.799

10.  Interleukin-35 induces regulatory B cells that suppress autoimmune disease.

Authors:  Ren-Xi Wang; Cheng-Rong Yu; Ivy M Dambuza; Rashid M Mahdi; Monika B Dolinska; Yuri V Sergeev; Paul T Wingfield; Sung-Hye Kim; Charles E Egwuagu
Journal:  Nat Med       Date:  2014-04-17       Impact factor: 53.440

View more
  15 in total

1.  An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion.

Authors:  John D Klement; Amy V Paschall; Priscilla S Redd; Mohammed L Ibrahim; Chunwan Lu; Dafeng Yang; Esteban Celis; Scott I Abrams; Keiko Ozato; Kebin Liu
Journal:  J Clin Invest       Date:  2018-11-05       Impact factor: 14.808

2.  The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells.

Authors:  Chunwan Lu; Priscilla S Redd; Jeffrey R Lee; Natasha Savage; Kebin Liu
Journal:  Oncoimmunology       Date:  2016-10-20       Impact factor: 8.110

3.  Th17 cell differentiation proceeds independently of IRF8.

Authors:  Dane M Newman; Patrick Sk Leung; Tracy L Putoczki; Stephen L Nutt; Erika Cretney
Journal:  Immunol Cell Biol       Date:  2016-05-03       Impact factor: 5.126

Review 4.  Uveitis: Molecular Pathogenesis and Emerging Therapies.

Authors:  Charles E Egwuagu; Sahar A Alhakeem; Evaristus C Mbanefo
Journal:  Front Immunol       Date:  2021-04-30       Impact factor: 7.561

5.  Interferon Regulator Factor 8 (IRF8) Limits Ocular Pathology during HSV-1 Infection by Restraining the Activation and Expansion of CD8+ T Cells.

Authors:  Lin Sun; Anthony J St Leger; Cheng-Rong Yu; Chang He; Rashid M Mahdi; Chi-Chao Chan; Hongsheng Wang; Herbert C Morse; Charles E Egwuagu
Journal:  PLoS One       Date:  2016-05-12       Impact factor: 3.240

6.  IRF8-dependent molecular complexes control the Th9 transcriptional program.

Authors:  Etienne Humblin; Marion Thibaudin; Fanny Chalmin; Valentin Derangère; Emeric Limagne; Corentin Richard; Richard A Flavell; Sandy Chevrier; Sylvain Ladoire; Hélène Berger; Romain Boidot; Lionel Apetoh; Frédérique Végran; François Ghiringhelli
Journal:  Nat Commun       Date:  2017-12-12       Impact factor: 14.919

7.  Increased expression of IRF8 in tumor cells inhibits the generation of Th17 cells and predicts unfavorable survival of diffuse large B cell lymphoma patients.

Authors:  Weijie Zhong; Xin Xu; Zhigang Zhu; Qinghua Du; Hong Du; Li Yang; Yanying Ling; Huabao Xiong; Qingshan Li
Journal:  Oncotarget       Date:  2017-07-25

8.  Two Genetic Variations in the IRF8 region are associated with Behçet's disease in Han Chinese.

Authors:  Yanni Jiang; Hong Wang; Hongsong Yu; Lin Li; Dengfeng Xu; Shengping Hou; Aize Kijlstra; Peizeng Yang
Journal:  Sci Rep       Date:  2016-01-22       Impact factor: 4.379

9.  Ocular Behcet's disease is associated with aberrant methylation of interferon regulatory factor 8 (IRF8) in monocyte-derived dendritic cells.

Authors:  Yiguo Qiu; Yunyun Zhu; Hongsong Yu; Shenglan Yi; Wencheng Su; Qingfeng Cao; Gangxiang Yuan; Aize Kijlstra; Peizeng Yang
Journal:  Oncotarget       Date:  2017-04-19

10.  Hypermethylation of Interferon Regulatory Factor 8 (IRF8) Confers Risk to Vogt-Koyanagi-Harada Disease.

Authors:  Yiguo Qiu; Hongsong Yu; Yunyun Zhu; Zi Ye; Jing Deng; Wencheng Su; Qingfeng Cao; Gangxiang Yuan; Aize Kijlstra; Peizeng Yang
Journal:  Sci Rep       Date:  2017-04-21       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.